종목토론카테고리
게시판버튼
게시글 제목
Teva Confirms September PDUFA Date for Fremanezumab게시글 내용
JERUSALEM--(BUSINESS WIRE)--May 23, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018. There are no additional data requests from the FDA.
“Our primary goal is to bring preventive treatment options to migraine patients as quickly as possible,” said Hafrun Fridriksdottir, Executive Vice President, Global R&D at Teva. “We are encouraged by the ongoing communications with the FDA as we work to bring this important therapy to patients.”
“We are incredibly excited to move this product forward in the review process and we are preparing to launch the product immediately when approved,” said Brendan O’Grady, Executive Vice President and Head of North America Commercial for Teva. “Migraine patients have waited years for new preventive treatments to enter the market.”
About Fremanezumab
Fremanezumab is an investigational therapy currently under review by the U.S. Food and Drug Administration (FDA) as a quarterly or monthly injection for the preventive treatment of migraine in adults.
Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. With limited availability of preventive treatment options, fremanezumab represents a potential new option to address a significant unmet medical need.
“Our primary goal is to bring preventive treatment options to migraine patients as quickly as possible,” said Hafrun Fridriksdottir, Executive Vice President, Global R&D at Teva. “We are encouraged by the ongoing communications with the FDA as we work to bring this important therapy to patients.”
“We are incredibly excited to move this product forward in the review process and we are preparing to launch the product immediately when approved,” said Brendan O’Grady, Executive Vice President and Head of North America Commercial for Teva. “Migraine patients have waited years for new preventive treatments to enter the market.”
About Fremanezumab
Fremanezumab is an investigational therapy currently under review by the U.S. Food and Drug Administration (FDA) as a quarterly or monthly injection for the preventive treatment of migraine in adults.
Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. With limited availability of preventive treatment options, fremanezumab represents a potential new option to address a significant unmet medical need.
게시글 찬성/반대
- 63추천
- 0반대
내 아이디와 비밀번호가 유출되었다? 자세히보기 →
운영배심원의견
운영배심원의견이란
운영배심원 의견이란?
게시판 활동 내용에 따라 매월 새롭게 선정되는
운영배심원(10인 이하)이 의견을 행사할 수 있습니다.
운영배심원 4인이 글 내리기에 의견을 행사하게 되면
해당 글의 추천수와 반대수를 비교하여 반대수가
추천수를 넘어서는 경우에는 해당 글이 블라인드 처리
됩니다.
운영배심원(10인 이하)이 의견을 행사할 수 있습니다.
운영배심원 4인이 글 내리기에 의견을 행사하게 되면
해당 글의 추천수와 반대수를 비교하여 반대수가
추천수를 넘어서는 경우에는 해당 글이 블라인드 처리
됩니다.
댓글목록